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We read with great interest the meta-analysis by Peng and
colleagues published in the International Journal of Infectious
Diseases, in which they questioned the effectiveness of procalci-
tonin (PCT)-guided antibiotic therapy (Peng et al., 2019). They
combined 16 randomized controlled trials (RCT), including 6452
critically ill patients with infections, and concluded that PCT-
guided antibiotic therapy does not lead to a decreased short-term
mortality. They also concluded that PCT-guided cessation of
antibiotics only reduces short-term mortality in patients with a
Sequential Organ Failure Assessment (SOFA) score of <8. It was,
therefore, suggested that PCT-guided antibiotic therapy would be
better suited to patients without multiple organ failure in the
emergency department or general ward. Unfortunately, we think
that this conclusion is neither correctly derived from the available
data nor plausible!
The question regarding whether the severity of illness, as
measured by the SOFA score, inﬂuences the effect of antibiotic
treatment in all RCTs on PCT-guided therapy, is a valid research
question. However, analyses should have been done at the
individual patient level. Indeed, a recent patient-level meta-
analysis on PCT-guided antibiotic therapy in 4482 septic patients in
the intensive care unit (ICU), by Wirz and colleagues, showed that
30-day mortality was lower in the PCT-guided group (Wirz et al.,
2018). Furthermore, when patients were divided into three
subgroups by organ failure (SOFA 0 to 6, 7 to 10, and 10 to 24),
the effects on mortality persisted. In our SAPS-trial on PCT
guidance (De Jong et al., 2016), we included 1546 ICU patients and
we demonstrated a signiﬁcant reduction in 28-day mortality in the
PCT group (p = 0.007). This effect on mortality persisted in the 587
patients with a SOFA score of 8 (p = 0.024).
Moreover, why should PCT-guided antibiotic therapy be better
suited to patients in the emergency department and general ward
or only patients with a SOFA score of <8? Obviously there are
numerous non-infectious inﬂammatory processes, e.g. trauma or
surgery, in which PCT can be elevated. Such conditions are
frequently seen in emergency departments and general wards, but
can also be encountered in the ICU. These conditions were well
balanced between the two groups in previous meta-analyses. We
therefore conclude that antibiotics should be started when an
infection is suspected and that PCT is particularly suited for the
cessation of antibiotic treatment, and we want to warn care-givers
that the sensitivity and speciﬁcity of a single PCT measurement inhttps://doi.org/10.1016/j.ijid.2019.09.027
1201-9712/© 2019 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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enough to start or withhold antibiotics based on PCT alone.
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